{
  "source": "PA-Med-Nec-Natpara.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2066-10\nProgram Prior Authorization/Medical Necessity\nMedication Natpara® (parathyroid hormone analog)\nP&T Approval Date 10/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 9/2021, 9/2022,\n9/2023, 9/2024\nEffective Date 11/17/2024\n1. Background:\nNatpara® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control\nhypocalcemia in patients with hypoparathyroidism.\nLimitations of Use:\nBecause of the potential risk of osteosarcoma, Natpara is recommended only for patients\no\nwho cannot be well-controlled on calcium supplements and active forms of vitamin D\nalone. It is available only through a restricted program called the Natpara REMS Program.\nNatpara was not studied in patients with hypoparathyroidism caused by calcium-sensing\no\nreceptor mutations.\nNatpara was not studied in patients with acute post-surgical hypoparathyroidism.\no\n2. Coverage Criteriaa:\nA. Hypoparathyroidism\n1. Initial Therapy\na. Natpara will be approved based on all of the following criteria:\n(1) Diagnosis of hypocalcemia resulting from chronic hypoparathyroidism\n-AND-\n(2) Patient is currently on adequate supplemental calcium and active vitamin D\n(e.g., calcitriol) therapy as evidenced by serum calcium (albumin corrected) >\n7.5 mg/dL\n-AND-\n(3) Prescribed by one of the following:\na. Endocrinologist\nb. Nephrologist\nAuthorization will be issued for 12 months\n© 2024 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization\na. Natpara will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response [e.g., total serum calcium level\n(albumin corrected) within the lower half of the normal range (approximately 8\nto 8.5 mg/dL]\n-AND-\n(2) Patient continues to take concomitant calcium supplementation that is sufficient\nto meet daily requirements\n-AND-\n(3) Prescribed by one of the following:\na. Endocrinologist\nb. Nephrologist\nAuthorization will be issued for 12 months\na State mandates ma",
    "ementation that is sufficient\nto meet daily requirements\n-AND-\n(3) Prescribed by one of the following:\na. Endocrinologist\nb. Nephrologist\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Natpara® [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; February 2023.\n2. Mannstadt, M, Clarke, BL, Vokes, T, et al. Efficacy and safety of recombinant human\nparathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-\ncontrolled, randomized, phase 3 study. The Lancet Diabetes & Endocrinology. 2013\nDec;1(4):275-83. PMID: 24622413\n3. Goltzman, David. Hypoparathyroidism. In: Post TW, ed. UpToDate. UpToDate; 2023. Accessed\nJuly 26, 2024.\nProgram Prior Authorization/Medical Necessity - Natpara (parathyroid hormone analog)\nChange Control\n10/2015 New program.\n9/2016 Annual Update. Updated references.\n9/2017 Annual review. Removed medical record submission requirement. Removed\n© 2024 UnitedHealthcare Services, Inc.\n2\nrequirement of concomitant active vitamin D therapy for reauthorization.\nUpdated references.\n9/2018 Annual review with no changes to coverage criteria.\n9/2019 Annual review with no changes to coverage criteria. Updated reference.\n9/2020 Annual review with no changes to coverage criteria. Updated reference.\n9/2021 Annual review with no changes to coverage criteria. Updated references.\n9/2022 Annual review with no changes to coverage criteria. Updated references.\n9/2023 Annual review with no changes to cove",
    "2021 Annual review with no changes to coverage criteria. Updated references.\n9/2022 Annual review with no changes to coverage criteria. Updated references.\n9/2023 Annual review with no changes to coverage criteria. Updated references.\n9/2024 Annual review. Updated initial authorization criteria and initial authorization\nduration to 12 months. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}